AbbVie, a research-based global biopharmaceutical company, today announced an update on the Phase 3 RESOLVE trial of ibrutinib in combination with chemotherapy agents nab-paclitaxel and gemcitabine versus placebo in combination with these chemotherapy agents in patients with metastatic pancreatic adenocarcinoma. IMBRUVICA is a first-in-class...
NORTH CHICAGO- AbbVie, a research-based global biopharmaceutical company, today announced an update on the Phase 3 RESOLVE trial of ibrutinib in combination with chemotherapy agents nab-paclitaxel and gemcitabine versus placebo in combination with these chemotherapy agents in patients with metastatic pancreatic adenocarcinoma.
Achilles Therapeutics receives CTA approval for Phase I/II Study in Non-Small Cell Lung Cancer Ground-breaking clinical trial in patients with significant unmet medical need to start this year. Stevenage, UK 21 January 2019 Achilles Therapeutics, a biopharmaceutical company developing personalised cancer immunotherapies, today announces that its
BRISBANE- Aimmune Therapeutics, Inc., a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the appointment of Andrew Oxtoby as Chief Commercial Officer. Mr. Oxtoby joins Aimmune from Eli Lilly and Company, where he most recently had responsibility for Lilly' s U.S. insulin business as Vi
ZUG, Switzerland& PETACH TIKVA, Israel Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, and Medison Pharma, Israel s leading commercial partner for innovative pharmaceuticals, announced today an exclusive agreement to commercialize ONPATTRO , the first-ever commercialized RNAi therapeutic, as well as other investigatio
CRANBURY- Amicus Therapeutics, a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced that four oral presentations and eight posters highlighting its development programs for Lysosomal Storage Disorders will be included at the 15th Annual WORLDSymposium 2019, to.
Antibe Therapeutics Inc., a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has received approval from Health Canada to initiate the second part of its Phase 2 B dose-ranging, efficacy study for its lead drug, ATB-346. The study will be conducted by Veristat, Inc. in approximately 35 clinical sites
Breda- argenx, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the closing of the exclusive, global collaboration and license agreement for cusatuzumab, a highly differentiated anti-CD70 SIMPLE Antibody, with...
AstraZeneca today announced that its partner Ironwood Pharmaceuticals, Inc. has received marketing authorisation from the National Medical Products Administration for Linzess in China for the treatment of adult patients with irritable bowel syndrome with constipation. Linzess is a first-in-class guanylate cyclase C receptor agonist and the...
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the global immunology market, today announced it will report results before the opening of trading and hold a webcast and conference call to discuss the results of its Phase 2, double-masked, head-to-head study of VOS 0.2% versus Restasis to evaluate the efficacy
The aging workforce in laboratory tests, the growing demand for high quality laboratory services and the growing need for fast results will lead to the expansion of the global market for automated microbiology testing over the next year. Automatic microbiology testing is an advanced technique in the field of microbiology that provides more accurate
CAMBRIDGE- AVROBIO, Inc. a Phase 2 clinical-stage gene therapy company, today announced that its investigational gene therapy candidate for cystinosis, AVR-RD-04, is cleared to begin a Phase 1/ 2 clinical trial, following acceptance of the investigational new drug application by the U.S. Food and Drug Administration. The Phase 1/ 2 clinical trial i
BerGenBio ASA, announces that the first patient has been dosed in a phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumour efficacy of ADCT-601, an AXL-targeting antibody drug conjugate, in patients with advanced solid tumours. ADCT-601 is composed of a humanised monoclonal antibody against human AXL discover
ADCT-601 uses a proprietary AXL antibody developed by BerGenBio and licensed to ADC Therapeutics for antibody drug conjugate development. ADCT-601 is BerGenBio's third clinical candidate targeting AXL Bergen, Norway, January 21 2019- BerGenBio ASA, announces that the first patient has been dosed in a phase I clinical trial evaluating the safety
A recently published report by Persistence Market Research projects that the global market for biologics safety testing will soar at a robust CAGR of 8.8% over the forecast period, 2017-2022. The report anticipates that approx. According to the report, North America will remain at the forefront of global expansion of biologics safety testing market
PETACH TIKVA- Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that it has entered into a definitive agreement with a single institutional investor to receive gross proceeds of approximately $2.35 million.
The topical medications have been used for a long time now for mild health issues and are also recommended by doctors in various circumstances or sometimes even for specific problems. Primarily you might have witnessed the usage of the topical medicines in skin related diseases or issues, or possibly for muscle pains. You might have guessed by now
Researchers sketched a vivid line Friday linking the dollars spent by drugmakers to woo doctors around the country to a vast opioid epidemic that has led to tens of thousands of deaths. Scott Hadland, the study s lead author and an addiction specialist at Boston Medical Center s Grayken Center for Addiction, has conducted previous studies con
Albany, NY 01/21/2019 Dry powder inhalers are used to deliver drugs in dry powdered form to the lungs of patients suffering from respiratory disorders. Pulmonary drug delivery has been gaining attention and acceptance in the past few years in the treatment of respiratory disorders due to advantages such as faster drug absorption, high bioavai
LYON- ERYTECH Pharma, a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, announced that a poster entitled' TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with...
Immunomedics Inc. said FDA issued a complete response letter for its BLA for sacituzumab govitecan to treat metastatic triple-negative breast cancer in a third-line setting. Shares of Immunomedics were off $4.78 to $13.31 for a loss of more than $900 million in market cap. Immunomedics said FDA is concerned about CMC issues, and will not require ne
Of the 21 drugs designed for delivery directly to the female genital tract, only four have a cost-effective, generic equivalent...
The post FDA grant to help increase generic drugs delivered intravaginally or by IUD appeared first on European Pharmaceutical Review.
BRUSSELS, 21 January 2019/ PRNewswire Policy/ Today, the first EU patients can use digital prescriptions issued by their home doctor when visiting a pharmacy in another EU country: Finnish patients are now able to go to a pharmacy in Estonia and retrieve medicine prescribed electronically by their doctor in Finland. Andrus Ansip, Vice President f
GeNeuro, a biopharmaceutical company developing new treatments for neurological and autoimmune diseases such as multiple sclerosis and type-1 diabetes, today announced positive safety and tolerability results from a Phase 1 study assessing the administration of high doses of temelimab to treat MS and other auto-immune diseases.